
Solid Biosciences (SLDB) Stock Forecast & Price Target
Solid Biosciences (SLDB) Analyst Ratings
Bulls say
Solid Biosciences Inc. exhibits a positive outlook due to its focused approach in developing gene therapies for Duchenne muscular dystrophy (DMD), demonstrated by significant mean improvements in the North Star Ambulatory Assessment (NSAA) among treated patients. The company's innovative treatment, del-zota, has shown a dose-dependent increase in dystrophin expression and clinically meaningful functional improvements across various endpoints, indicating strong therapeutic potential. Furthermore, advancements in antibody-oligonucleotide conjugates and their associated benefits, such as enhanced efficacy and convenience over traditional therapies, suggest solid growth prospects within the competitive landscape of neuromuscular disease treatments.
Bears say
The analysis indicates a negative outlook for Solid Biosciences Inc, primarily due to disappointing clinical data, including a decline in NSAA scores and a significant reduction in dystrophin expression levels. The company's projections face considerable risks stemming from potential safety issues and regulatory challenges that may hinder the approval of their key therapy, SGT-003. Furthermore, results from larger studies suggest lower efficacy compared to earlier trials, amplifying concerns about the company's future financial performance and the viability of their product pipeline.
This aggregate rating is based on analysts' research of Solid Biosciences and is not a guaranteed prediction by Public.com or investment advice.
Solid Biosciences (SLDB) Analyst Forecast & Price Prediction
Start investing in Solid Biosciences (SLDB)
Order type
Buy in
Order amount
Est. shares
0 shares